Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.71 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | MGAM | O43451 | 6/20 | 0.60 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | CDC25C | P30307 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3912373 | 0.84 | NQO1 (0.65) | NQO1MAOAMGAMMAOBALDH1A1 | |
| SCHEMBL11568363 | 0.82 | NQO1 (0.61) | NQO1MAOAMGAMMAOBALDH1A1 | |
| SCHEMBL29953437 | 0.82 | NQO1 (0.61) | NQO1MAOAMGAMMAOBALDH1A1 | |
| SCHEMBL8493787 | 0.81 | PDE2A (0.56) | NQO1MAOAMGAMKDM4EMEN1 | |
| SCHEMBL14170077 | 0.80 | NQO1 (0.78) | NQO1MAOAMGAMMAOBALDH1A1 | |
| SCHEMBL6190126 | 0.79 | NQO1 (0.58) | NQO1MAOAMGAMMAOBPOLB | |
| SCHEMBL3275885 | 0.79 | NQO1 (0.76) | NQO1MAOAMGAMMAOBALDH1A1 | |
| SCHEMBL14169888 | 0.79 | MGAM (0.65) | NQO1MAOAMGAMMAOBALDH1A1 | |
| SCHEMBL14170081 | 0.78 | MGAM (0.64) | NQO1MAOAMGAMMAOBALDH1A1 | |
| SCHEMBL11846218 | 0.78 | NQO1 (0.57) | NQO1MAOAMGAMMAOBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4845121-A | Aci-reductone compounds belonging to the 6,7-disubstituted-3,4-dihydro benzopyan-2H-one class having antiaggregatory properties | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1989-07-04 | — | — | US | claimed |
| US-20110021621-A1 | Drug for treating circulatory insufficiency | ACTIVUS PHARMA CO., LTD. (JP) | 2011-01-27 | — | — | US | disclosed |
| US-20110021621-A1 | Drug for treating circulatory insufficiency | ACTIVUS PHARMA CO., LTD. (JP) | 2011-01-27 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20090099256-A1 | Drug for Treating Circulatory Insufficiency | ACTIVUS PHARMA CO., LTD. (JP) | 2009-04-16 | — | — | US | disclosed |
| US-20090099256-A1 | Drug for Treating Circulatory Insufficiency | ACTIVUS PHARMA CO., LTD. (JP) | 2009-04-16 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| US-5028720-A | 6,7-nonsubstituted and 6,7-disubstituted-3,4-dihydroxy benzopyran-2H-one compounds having antiaggregatory properties and processes for their preparation | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1991-07-02 | — | — | US | disclosed |
| US-4845121-A | Aci-reductone compounds belonging to the 6,7-disubstituted-3,4-dihydro benzopyan-2H-one class having antiaggregatory properties | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1989-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | NQO1 4048/4885MAOA 32/4885MGAM 4772/4885 |
| US-20110021621-A1 | Drug for treating circulatory insufficiency | NPR1, TNNI3, NPR3 | NQO1 1027/4885MAOA 2470/4885MGAM 2937/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | NQO1 721/4885MAOA 1703/4885MGAM 2941/4885 |
| US-20090099256-A1 | Drug for Treating Circulatory Insufficiency | NPR1, TNNI3, NPR3 | NQO1 1027/4885MAOA 2470/4885MGAM 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.